(Q50673876)

English

A Phase III trial to investigate the timing of radiotherapy for prostate cancer with high-risk features: background and rationale of the Radiotherapy -- Adjuvant Versus Early Salvage (RAVES) trial.

scientific article published in March 2014

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

17 March 2018

http://europepmc.org/abstract/MED/24894850

A Phase III trial to investigate the timing of radiotherapy for prostate cancer with high-risk features: background and rationale of the Radiotherapy -- Adjuvant Versus Early Salvage (RAVES) trial. (English)

1 reference

Europe PubMed Central

17 March 2018

http://europepmc.org/abstract/MED/24894850

radiation therapy

0 references

phase III clinical trial

0 references

prostate cancer

1 reference

based on heuristic

inferred from title

object named as

Jeremy Millar

12

0 references

author name string

Maria Pearse

1

1 reference

Europe PubMed Central

17 March 2018

http://europepmc.org/abstract/MED/24894850

Carol Fraser-Browne

2

1 reference

Europe PubMed Central

17 March 2018

http://europepmc.org/abstract/MED/24894850

Ian D Davis

3

1 reference

Europe PubMed Central

17 March 2018

http://europepmc.org/abstract/MED/24894850

Gillian M Duchesne

4

1 reference

Europe PubMed Central

17 March 2018

http://europepmc.org/abstract/MED/24894850

Richard Fisher

5

1 reference

Europe PubMed Central

17 March 2018

http://europepmc.org/abstract/MED/24894850

Mark Frydenberg

6

1 reference

Europe PubMed Central

17 March 2018

http://europepmc.org/abstract/MED/24894850

Annette Haworth

7

1 reference

Europe PubMed Central

17 March 2018

http://europepmc.org/abstract/MED/24894850

Chakiath Jose

8

1 reference

Europe PubMed Central

17 March 2018

http://europepmc.org/abstract/MED/24894850

David J Joseph

9

1 reference

Europe PubMed Central

17 March 2018

http://europepmc.org/abstract/MED/24894850

Tee S Lim

10

1 reference

Europe PubMed Central

17 March 2018

http://europepmc.org/abstract/MED/24894850

John Matthews

11

1 reference

Europe PubMed Central

17 March 2018

http://europepmc.org/abstract/MED/24894850

Mark Sidhom

13

1 reference

Europe PubMed Central

17 March 2018

http://europepmc.org/abstract/MED/24894850

Nigel A Spry

14

1 reference

Europe PubMed Central

17 March 2018

http://europepmc.org/abstract/MED/24894850

Colin I Tang

15

1 reference

Europe PubMed Central

17 March 2018

http://europepmc.org/abstract/MED/24894850

Sandra Turner

16

1 reference

Europe PubMed Central

17 March 2018

http://europepmc.org/abstract/MED/24894850

Scott G Williams

17

1 reference

Europe PubMed Central

17 March 2018

http://europepmc.org/abstract/MED/24894850

Kirsty Wiltshire

18

1 reference

Europe PubMed Central

17 March 2018

http://europepmc.org/abstract/MED/24894850

Henry H Woo

19

1 reference

Europe PubMed Central

17 March 2018

http://europepmc.org/abstract/MED/24894850

Andrew Kneebone

20

1 reference

Europe PubMed Central

17 March 2018

http://europepmc.org/abstract/MED/24894850

publication date

1 March 2014

1 reference

Europe PubMed Central

17 March 2018

http://europepmc.org/abstract/MED/24894850

BJU International

1 reference

Europe PubMed Central

17 March 2018

http://europepmc.org/abstract/MED/24894850

113 Suppl 2

1 reference

Europe PubMed Central

17 March 2018

http://europepmc.org/abstract/MED/24894850

7-12

1 reference

Europe PubMed Central

17 March 2018

http://europepmc.org/abstract/MED/24894850

Adjuvant radiotherapy for pathological T3N0M0 prostate cancer significantly reduces risk of metastases and improves survival: long-term followup of a randomized clinical trial

1 reference

https://api.crossref.org/works/10.1111%2FBJU.12623

21 January 2018

Phase III postoperative adjuvant radiotherapy after radical prostatectomy compared with radical prostatectomy alone in pT3 prostate cancer with postoperative undetectable prostate-specific antigen: ARO 96-02/AUO AP 09/95.

1 reference

https://api.crossref.org/works/10.1111%2FBJU.12623

21 January 2018

Post-prostatectomy radiation therapy: consensus guidelines of the Australian and New Zealand Radiation Oncology Genito-Urinary Group

1 reference

https://api.crossref.org/works/10.1111%2FBJU.12623

21 January 2018

Adjuvant radiotherapy for pathologically advanced prostate cancer: a randomized clinical trial

1 reference

https://api.crossref.org/works/10.1111%2FBJU.12623

21 January 2018

Predicting the outcome of salvage radiation therapy for recurrent prostate cancer after radical prostatectomy

1 reference

https://api.crossref.org/works/10.1111%2FBJU.12623

21 January 2018

Prostate cancer-specific survival following salvage radiotherapy vs observation in men with biochemical recurrence after radical prostatectomy

1 reference

https://api.crossref.org/works/10.1111%2FBJU.12623

21 January 2018

Health-related quality of life results in pathologic stage C prostate cancer from a Southwest Oncology Group trial comparing radical prostatectomy alone with radical prostatectomy plus radiation therapy.

1 reference

https://api.crossref.org/works/10.1111%2FBJU.12623

21 January 2018

Identifiers

10.1111/BJU.12623

1 reference

Europe PubMed Central

17 March 2018

http://europepmc.org/abstract/MED/24894850

1 reference

Europe PubMed Central

17 March 2018

http://europepmc.org/abstract/MED/24894850

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q50673876&oldid=1966833775"